Skip to main content
. 2021 Feb 19;5(12):1245–1253. doi: 10.1016/j.oret.2021.02.005

Table 1.

Comparison of Patients Who Participated Compared with Those Who Did Not Participate

Total (n = 2274) Signed Up (n = 732) Declined (n = 2042) P Value Adjusted P Value
Age (yrs), mean ± SD 68 ± 13 62 ± 14 69 ± 13 0.021
Female gender, no. (%) 1237 (45) 279 (38) 958 (47) < 0.001
Race, no. (%)
 Chinese 1992 (72) 398 (54) 1594 (78) 0.021 0.12
 Indian 245 (9) 65 (9) 180 (9)
 Malay 235 (8) 57 (8) 178 (9)
 Others 302 (11) 212 (29) 90 (4)
Living with family, no. (%) 2626 (95) 719 (98) 1907 (93) 0.014 0.021
Diagnosis, no. (%)
 DME 263 (9) 136 (19) 127 (6) < 0.001 < 0.001
 DR 571 (21) 201 (27) 370 (18)
 Neovascular AMD 881 (32) 136 (19) 745 (36)
 Nonneovascular AMD 330 (12) 138 (19) 192 (9)
 RVO 400 (14) 73 (10) 327 (16)
 Other 329 (12) 48 (7) 281 (14)
Bilateral eyes affected, no. (%) 1017 (37) 296 (40) 721 (35) 0.072 0.32
VA (letters) mean ± SD
 Better eye 70 ± 13 69 ± 14 74 ± 12 < 0.001 0.93
 Worse eye 50 ± 25 49 ± 25 61 ± 22 < 0.001 < 0.001
Patients with intended follow-up (> 4 mos), no. (%) 803 (29) 395 (54) 408 (20) < 0.001 < 0.001
Patients receiving active treatment, no. (%) 984 (35) 152 (21) 832 (41) < 0.001 0.023

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy; RVO = retinal vein occlusion; SD = standard deviation; VA = visual acuity.

Adjusted for age and gender.

Adjusted for age, gender, and ethnicity.

Adjusted for age, gender, ethnicity, and diagnosis.